MKC-1

CAT: 0804-HY-13691-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13691-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family[1][2][3].
CAS Number
[125313-92-0]
Product Name Alternative
Ro-31-7453
UNSPSC
12352005
Target
Akt; Apoptosis; Microtubule/Tubulin; Mitosis; mTOR
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mkc-1.html
Purity
99.78
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(C(C1=CN(C)C2=C1C=CC=C2)=C3C4=CN(C)C5=C4C=CC([N+]([O-])=O)=C5)NC3=O
Molecular Formula
C22H16N4O4
Molecular Weight
400.39
References & Citations
[1]Wang M, et al. The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent. Nucl Med Biol. 2010 Oct;37 (7) :763-75.|[2]Burke P, et al. MKC-1 significantly increases survival of mice bearing renal cell carcinoma Caki-1 xenograft tumors through inhibition of the Akt/mTOR pathway[J]. Molecular Cancer Therapeutics, 2007 (12) :3524S-3525S.|[3]Faris JE, et al. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug;30 (4) :1614-20.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Popular Products